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PCirculating Lipid Hydroperoxides Predict Cardiovascular
Events in Patients With Stable Coronary Artery Disease
The PREVENT Study
Mary F. Walter, PHD,* Robert F. Jacob, PHD,*‡ Rebekah E. Bjork, BS,* Barrett Jeffers, PHD,†
Jan Buch, MD,† Yoshiko Mizuno, MD, PHD,*‡ R. Preston Mason, PHD,*‡ on behalf of the
PREVENT Investigators
Beverly and Boston, Massachusetts; and New York, New York
Objectives This study was designed to determine the predictive value of lipid hydroperoxide (LOOH) levels for adverse car-
diovascular outcomes in patients with stable coronary artery disease (CAD).
Background Oxidative modification of circulating lipids contributes to inflammation and endothelial dysfunction, which are
hallmark features of atherosclerosis. A serum biomarker of oxidation is LOOH, which is a primary product of
fatty acid peroxidation.
Methods Serum LOOH levels were measured and correlated with clinical events over a 3-year period in 634 patients with
angiographic evidence of CAD.
Results Baseline LOOH levels in the highest quartile were associated with hazard ratios of 3.24 (95% confidence interval
[CI] 1.86 to 5.65; p  0.0001) for nonfatal vascular events (n  149), 1.80 (95% CI 1.13 to 2.88; p  0.014)
for major vascular procedures (n  139), and 2.23 (95% CI 1.44 to 3.44; p  0.0003) for all vascular events
and procedures. Baseline LOOH levels correlated with serum levels of soluble intercellular adhesion molecule-1
(p  0.001) and thiobarbituric acid reactive substances (p  0.001) as well as the mean percent change in ste-
nosis for large segments 50% stenosed (p  0.048). A multivariate proportional hazards model, adjusted for
traditional risk factors and inflammatory markers, showed an independent effect of LOOH on nonfatal vascular
events, vascular procedures, and all events or procedures. Amlodipine treatment was associated with reduced
cardiovascular events and changes in LOOH levels compared with placebo.
Conclusions Elevated LOOH levels were predictive of nonfatal vascular events and procedures in patients with stable CAD,
independent of traditional risk factors and inflammatory markers. (J Am Coll Cardiol 2008;51:1196–202)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.051d
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exidative modification of low-density lipoprotein (LDL)
nd cellular lipids contributes to foam cell formation,
ndothelial dysfunction, and destructive inflammatory pro-
esses associated with atherosclerosis (1–3). Lipid hydroper-
xides (LOOH) are generated from polyunsaturated fatty acids
nd represent primary end products of the lipid peroxidation
ascade. Circulating levels of LOOH have been shown to be
ignificantly elevated in association with myocardial ischemia
4) and cardiovascular risk factors (5–9). With sustained
xposure to reactive oxygen species, LOOH undergoes further
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rs. Jeffers and Buch are employees of Pfizer Inc. Dr. Mason has received honoraria
nd independent research grants from Pfizer Inc.b
Manuscript received June 19, 2007; revised manuscript received November 12,
007, accepted November 12, 2007.ecomposition to reactive aldehydes, such as malondialdehyde
MDA) and 4-hydroxynonenal. We recently reported that
evels of MDA (measured as thiobarbituric acid reactive
ubstances [TBARS]) were highly predictive of cardiovas-
ular events, independent of traditional risk factors (10). In
his earlier study, levels of TBARS did not predict changes
n large stenotic lesions. This has led to our hypothesis that
rimary end products of lipid peroxidation may be useful,
nd perhaps more sensitive, diagnostic biomarkers of car-
iovascular disease (CVD) progression.
This longitudinal study evaluated the predictive value of
OOH levels in 634 patients with stable CAD from
REVENT (Prospective Randomized Evaluation of the
ascular Effects of Norvasc Trial), a prospective, double-
lind clinical trial. Patients in this study had angiographic
vidence of coronary artery disease (CAD) and normalized
lood pressure at baseline. The participants were random-
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March 25, 2008:1196–202 Lipid Hydroperoxide Levels and Cardiovascular Riskzed to treatment with either amlodipine or placebo. The
rimary outcome was the average 36-month angiographic
hange in mean minimal diameters of segments with a
aseline diameter stenosis of 30%. Amlodipine treatment
10 mg/day) did not slow angiographic progression of
oronary atherosclerosis relative to placebo but significantly
lowed carotid artery atherosclerosis, which was assessed
ltrasonographically (11). Amlodipine was associated with
ewer cases of unstable angina pectoris and coronary revas-
ularization procedures, although treatment did not signif-
cantly decrease mortality or major vascular events (11). The
enefits seen with amlodipine treatment may be attributed to
arious calcium-dependent and -independent mechanisms,
ncluding its reported antioxidant activity (12–15).
In this study, we evaluated LOOH levels in serum
amples collected from patients at baseline and at the end of
ach 12-month period during the 3-year study. The levels of
OOH were measured spectrophotometrically (16,17). The
ssociation of LOOH with clinical events and procedures
as evaluated in univariate and multivariate models adjusted
or inflammatory markers (high sensitivity C-reactive pro-
ein [hs-CRP], soluble intercellular adhesion molecule
sCAM]-1, interleukin [IL]-6) and other risk factors (age,
ender, lipids, body mass index [BMI], and blood pressure).
ethods
eneral design features. The PREVENT was a multi-
enter, randomized, placebo-controlled, double-blind clin-
cal trial of patients who had angiographic evidence of CAD
11). Men and women (30 to 80 years of age) were
andomized if there was angiographic evidence of 1 focal
oronary lesion of 30% diameter stenosis (nonintervened
nd noninfarcted) and the presence of 1 lesion with a 5%
o 20% stenosis that was not in a vessel with a 60% lesion.
ther eligibility criteria included diastolic blood pressure
DBP) of 95 mm Hg, total cholesterol of 325 mg/dl,
nd fasting blood glucose of 200 mg/dl. Randomization
as stratified according to clinical center and history of
ercutaneous transluminal coronary angioplasty. Study
edication was initiated at 5 mg daily and increased to 10
g daily after 2 weeks if tolerated. The final study angio-
ram was scheduled 36 months after randomization, 7 to 10
ays after the study medication was stopped.
onitoring for clinical events and adverse experiences. The
re-specified clinical events were all-cause mortality and the
ccurrence of major fatal/nonfatal vascular events or proce-
ures. An external events classification committee blinded
o treatment assignment classified the events as death,
yocardial infarction, stroke, hospitalized heart failure, or
ospitalized episodes of unstable angina. Confirmation of
nstable angina required hospitalization for typical chest
ain and either evidence of myocardial ischemia (electro-
ardiogram or stress test evidence, or new angiographic
ndings of disease) or an indication that this pain was
imilar to that of previously documented ischemia. ngiographic methods and
utcomes. The progression of
arly atherosclerotic segments
as determined on the basis of a
hange in mean minimal diame-
er with quantitative coronary
ngiography (18,19). Atheroscle-
otic segments were defined as
oronary segments with a diam-
ter stenosis of 30% at base-
ine. Up to 12 coronary segments
ere used in the analysis of dis-
ase progression (20). Vessels
hat underwent a procedure at or
efore baseline were excluded
rom the analyses. A certified
eader who was blinded to treat-
ent assignment and the tempo-
al sequencing of films read pair-
ise the baseline and follow-up
lms.
easurement of serum LOOH
evels. Serum samples were
vailable from 634 fasting partic-
pants at the beginning of the
tudy (baseline) and at the end of
ach of the 3 years. Samples were
tored at –70°C without the ad-
ition of exogenous antioxidants
rior to LOOH analysis. After
hawing the samples, measure-
ents of LOOH were per-
ormed in triplicate for each of
,975 samples using the ferrous
xidation of xylenol orange
FOX) 2 assay (16,17). Serum
ipid hydroperoxides were mea-
ured by oxidation of ferrous iron
n the presence of xylenol orange. In this method, ferrous
ron is oxidized to ferric iron by hydroperoxides. This
roduct then forms a complex with xylenol orange to yield
chromophore that can be detected spectrophotometrically
t 560 nm. No lipid extraction step is necessary and the
ssay measures total plasma lipid hydroperoxides (i.e., the
um of cholesterol, triacylglycerol, and phospholipid hy-
roperoxides contained in all lipoprotein fractions).
easurement of TBARS. Malondialdehyde levels were
valuated by measuring serum TBARS. These measure-
ents were performed in duplicate for each of the 2,975
amples using the method of Carbonneau et al. (21), with
light modifications. Briefly, 50 l of 10 mol/l sodium
ydroxide (NaOH) was added to 0.5 ml of serum and
ncubated at 60°C for 30 min. The sample was then
cidified to pH 1.0 with 500 l of 586 g/l perchloric acid.
fter centrifugation, 300 l of supernatant was added to 50
Abbreviations
and Acronyms
BMI  body mass index
CAD  coronary artery
disease
CV  coefficients of
variation
CVD  cardiovascular
disease
DBP  diastolic blood
pressure
FOX  ferrous oxidation of
xylenol orange
HDL  high-density
lipoprotein
HPLC  high-performance
liquid chromatography
hs-CRP  high sensitivity
C-reactive protein
IL  interleukin
LDL  low-density
lipoprotein
LOOH  lipid hydroperoxide
Lp-PLA2  lipoprotein-
associated phospholipase A2
MDA  malondialdehyde
MI  myocardial infarction
QC  quality control
SBP  systolic blood
pressure
sICAM  soluble
intercellular adhesion
molecule
TBA  thiobarbituric acid
TBARS  thiobarbituric
acid reactive substancesl of thiobarbituric acid (TBA) (10 g/l in 50 mmol/l
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Lipid Hydroperoxide Levels and Cardiovascular Risk March 25, 2008:1196–202hosphate buffer, pH 7.0) and heated at 100°C for 30 min.
he sample was cooled and 100 l were removed for
igh-performance liquid chromatography (HPLC) analysis.
The MDA-TBA complex was separated from other
ossible TBA reactants using reverse-phase HPLC on a
arian ProStar system (Varian Inc., Palo Alto, California)
oupled to a spectrophotometric detector (operating at 532
m) and a fluorescence detector (excitation  515 nm,
mission  553 nm) on a 150 mm  4.6 mm Adsorbo-
phere (Alltech Associates Inc., Deerfield, Illinois) C18
olumn with 5-m particle size. The purpose for using
everse-phase HPLC followed by quantitation with both
pectrophotometry and fluorescence was to eliminate other
ldehydes that react with TBA and have absorbance char-
cteristics at 532 nm (22–24). The flow rate was 1 ml/min
nd the mobile phase was 80% phosphate buffer (10 mmol/l,
H 5.8) with 20% methanol. A standard curve was run at
he start, middle, and end of each sample set analysis using
,1,3,3-tetraethoxypropane as a standard. Peak areas were
etermined using Varian Star Chromatography Worksta-
ion software.
easurement of serum hs-CRP, IL-6 and sICAM-1. High
ensitivity C-reactive protein levels were measured using the N
atex mono assay (Dade Behring Inc., Newark, Delaware)
ith a detection limit of 0.21 mg/l. Samples with values
elow the limit of detection were recorded as 0.21 mg/l;
he value 0.20 mg/l was incorporated for statistical analyses.
ntra- and interassay precision for the low quality control
QC) (0.46 mg/l) had coefficients of variation (CVs) of
.9% and 14.8%, respectively. Serum soluble intercellular
dhesion molecule-1 levels were measured with the Param-
ter Human sICAM-1 Immunoassay Kit (R&D Systems,
inneapolis, Minnesota), with a range of 0 to 588 ng/ml.
ntra- and interassay precision for the middle QC (282.7
g/ml) had CVs of 9.0% and 9.5%, respectively.
nterleukin-6 levels were measured using the Quantikine
S IL-6 R&D Systems kit, which had an assay range of
.156 to 10 pg/ml. Intra- and interassay precision for the
ow QC (0.338 pg/ml) had CVs of 9.9% and 14.4%,
espectively. All measurements were made by Esoterix
oagulation (Aurora, Colorado).
tatistical analysis. All statistical analyses were performed
sing SAS Version 8.2 (SAS Institute Inc, Cary, North
arolina) with alpha set to 0.05. Simple descriptive statistics
ere used to describe the population. For clinical outcomes,
roportional hazards regression models were used to obtain
azard ratios and associated 95% confidence intervals (CIs).
he first proportional hazards model used baseline LOOH
nd treatment as covariates for each clinical outcome (major
ascular events, hospitalizations for angina, coronary artery
ypass grafting, PTCA, and major vascular procedures). To
urther investigate the impact of LOOH on clinical out-
omes, a proportional hazards model was performed using
uartiles of baseline LOOH with the reference group being
hose in the lowest quartile. The univariate effect of LOOH
n major vascular events, nonfatal vascular events, vascular
P
srocedure, and all vascular events and procedures was also
ested in a multivariate Cox proportional hazards regression
odel adjusted for inflammatory markers (sICAM-1, IL-6,
s-CRP) and known cardiovascular disease (CVD) risk
actors, including age, gender, total cholesterol, high-
ensity lipoprotein (HDL), LDL, triglycerides, systolic
lood pressure (SBP), DBP, and BMI.
Pearson’s correlation coefficients were used to assess the
orrelation between LOOH and coronary angiography out-
omes measurements (e.g., all segments, segments stenosed
30%, segments stenosed 30% and 50% and segments
tenosed 50%) as well as LOOH and changes in patient
haracteristics (e.g., change in SBP, change in DBP, change
n HDL, change in LDL and change in triglycerides). The
-values were calculated from the Spearman rank correla-
ion coefficient.
esults
aseline characteristics. The baseline patient characteris-
ics of the study cohort are shown in Table 1 and were well
atched as a function of treatment with amlodipine or
lacebo, as previously described in detail (11). There were
o clinically relevant differences in the baseline characteris-
ics of the patients who did and did not participate in the
iomarker study due to availability of adequate serum
amples.
REVENT: Baselineescription of Patients (n  634)
Table 1 PREVENT: BaselineDescription of Patients (n  634)
Mean*
Variable
Age (yrs) 57.2 9.6
Male (%) 80.9
Female (%) 19.1
Total cholesterol (mg/dl) 217.9 39.1
HDL cholesterol (mg/dl) 45.7 11.5
LDL cholesterol (mg/dl) 132.4 36.1
Triglycerides (mg/dl) 203.7 131.7
Average SBP (mm Hg) 129.0 17.4
Average DBP (mm Hg) 78.6 9.1
BMI (kg/m  m) 27.9 4.6
Current smoker (%) 24.9
Past smoker (%) 54.9
Prior MI (%) 47.3
Prior angina (%) 51.6
Medication use (%)
Calcium channel blocker 33.8
ACE inhibitor 9.1
Diuretic 11.8
Beta-blocker 62.8
Nitrates 63.8
Lipid-lowering agent 27.3
Values are mean  standard deviation unless indicated.
ACE angiotensin-converting enzyme; BMI body mass index; DBP diastolic blood pressure;
DL  high-density lipoprotein; LDL  low-density lipoprotein; MI  myocardial infarction;
REVENT  Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial; SBP 
ystolic blood pressure.
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March 25, 2008:1196–202 Lipid Hydroperoxide Levels and Cardiovascular Risklinical events. During the study, there were 51 major
ascular events, such as fatal/nonfatal myocardial infarction
MI) and stroke; 149 hospitalizations for nonfatal cardio-
ascular events (mainly unstable angina); and 139 patients
lso underwent a major vascular procedure, such as PTCA/
ABG (11).
ipid hydroperoxide levels and clinical events. Table 2
hows the relationship between measured baseline levels of
OOH and cardiovascular events in PREVENT. Baseline
OOH levels in the highest quartile were associated with
azard ratios of 3.24 (95% CI 1.86 to 5.65; p  0.0001) for
onfatal vascular events (n  149), 1.80 (95% CI 1.13 to
.88; p  0.014) for major vascular procedures (n  139),
nd 2.23 (95% CI 1.44 to 3.44; p  0.0003) for all vascular
vents and procedures. The absolute mean levels of LOOH
n patients at baseline with and without specific vascular
vents and procedures events are shown in Table 3. At base-
ine, the overall mean absolute level of LOOH was 36.5 
8.1 mol/l. The significant univariate effect of LOOH
een on major vascular events, nonfatal vascular events,
ascular procedures, and all vascular events and procedures
s also seen in a multivariate model, adjusting for inflam-
atory markers and known CVD risk factors. Specifically, a
ultivariate Cox proportional hazards regression analysis
as performed in which the following variables were in-
luded: LOOH, inflammatory markers (sICAM-1, IL-6,
s-CRP), age, gender, total cholesterol, HDL, LDL, tri-
lycerides, SBP, DBP, and BMI. After adjusting for all of
hese variables, LOOH levels showed an independent effect
n nonfatal vascular events, vascular procedures, and all
ascular events and procedures. The data presented in
igure 1 demonstrate that participants with the highest
aseline LOOH levels were at increased risk for experienc-
ng major events and/or procedures.
ipid hydroperoxide levels and inflammatory markers. We
easured serum levels of 3 different inflammatory markers
t baseline from identical samples. The median (25th, 75th
ercentile) levels at baseline for IL-6, sICAM-1, and
s-CRP were 2.7 pg/ml (1.7, 4.3), 2.1 ng/ml (1.7, 2.5), and
.5 mg/l (1.2, 5.5), respectively. A significant correlation of
OOH (p  0.001) with levels of sICAM-1 was observed,
ith a correlation coefficient of 0.265; however, as reported
n Table 4, baseline levels of LOOH did not correlate with
ither hs-CRP, an acute-phase reactant, or with levels
f IL-6.
PREVENT: Predictive Value of LOOH Serum Leve
Table 2 PREVENT: Predictive Value of LOOH
Cardiovascular Event Num
Major vascular events (fatal/nonfatal MI, stroke)
Hospitalizations for angina
Major vascular procedures (CABG/PTCA)
All major vascular events and proceduresCABG  coronary artery bypass graft; CI  confidence interval; HR  haz
RR  relative risk; other abbreviations as in Table 1.ipid hydroperoxide levels and advanced products of
ipid peroxidation. The decomposition of LOOH into
ore advanced products of lipid peroxidation, such as
DA, were measured and compared with levels of LOOH.
s shown in Table 4, baseline levels of MDA (measured as
BARS) correlated with LOOH levels. The correlation
oefficient was 0.158 and highly significant (p  0.001).
ipid hydroperoxide levels and amlodipine treatment. The
edian level at baseline for LOOH was 36.5  28.1
mol/l. Amlodipine treatment was associated with a smaller
ecrease in levels of LOOH (16.4 mol/l) versus placebo
21.5 mol/l) treated patients over the 3-year period (p
.032). Patients on amlodipine experienced a 31% reduction
n the relative risk of a major documented vascular event or
rocedure (p  0.01), as previously reported in detail (11).
ipid hydroperoxide levels and angiographic measure-
ents. In segments with 50% stenosis, baseline LOOH
evels correlated significantly with the mean percent change
n stenosis (n  246; p  0.048). By contrast, there was no
ssociation with the inflammatory markers (IL-6,
ICAM-1, hs-CRP) or levels of TBARS. In segments with
30% or 30% to 50% stenosis (n  540), there was no
ignificant association with serum LOOH levels (p 
.963).
ipid hydroperoxide levels and patient characteristics. Levels
f LOOH also did not correlate with baseline demographics
ncluding gender, age, history of smoking, previous angina,
r MI. In addition, LOOH baseline levels did not associate
ignificantly with the patient’s family history of either MI or
udden death from CVD.
iscussion
he key finding of this longitudinal study was that LOOH
as a significant independent predictor of nonfatal cardio-
ascular events and procedures in patients with stable CAD.
evels of LOOH also correlated with a key marker of
ndothelial dysfunction (sICAM-1) and larger stenotic
esions (50%) in these angiographically documented CAD
atients. It was further observed that the association of
OOH levels and CVD risk was independent of traditional
isk factors and inflammatory markers (hs-CRP and IL-6).
These data indicate prognostic utility with LOOH for
ardiovascular events in patients with stable CAD, along
ith certain aspects of plaque progression and remodeling.
s most unstable plaques are associated with smaller ste-
aseline) in Highest Quartile
m Levels (Baseline) in Highest Quartile
ith Event HR 95% CI for RR p Value
1 1.85 0.82–4.20 0.138
9 3.24 1.86–5.65 0.0001
9 1.80 1.13–2.88 0.014
0 2.23 1.44–3.44 0.0003ls (B
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19ard ratio; PTCA  percutaneous transluminal coronary angioplasty;
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Lipid Hydroperoxide Levels and Cardiovascular Risk March 25, 2008:1196–202otic lesions, we speculate that LOOH levels reflect the
hronic phase of CAD and may not become elevated in
atients with acute coronary syndrome in which inflamma-
ory biomarkers (e.g., hs-CRP) are commonly high. The
bility to determine CVD risk with LOOH in these
atients was similar to that observed for MDA (measured
y TBARS), as previously reported (10). However, levels of
DA did not correlate with the percent change in large
tenotic lesions and were unaffected by amlodipine treat-
ent (10). Thus, there may be differences in the predictive
alue of primary versus secondary end products of oxidation
Figure 1 Quartile Analysis of Serum LOOH
Levels and Risk for Cardiovascular Events
Analysis of baseline lipid hydroperoxide (LOOH) levels in patients with docu-
mented coronary artery disease for combined (A) and individual (B) events and
procedures. CABG  coronary artery bypass graft; CHF  congestive heart fail-
ure; HR  hazard ratio; MI  myocardial infarction; PTCA  percutaneous
transluminal coronary angioplasty.
PREVENT: Comparative Absolute LOOH Serum LWith Specific Vascular Events and Procedures a
Table 3 PREVENT: Comparative Absolute LOWith Specific Vascular Events and
Cardiovascular Event
Patie
Events/
Mean, mo
Major vascular events (MI, stroke) 41.2
Nonfatal vascular events (angina/CHF) 45.1
Major vascular procedures (CABG/PTCA) 43.0
All vascular events and procedures 42.0
*Lipid hydroperoxide (LOOH) levels for patients with versus without ev
CHF  congestive heart failure; other abbreviations as in Tables 1 awith respect to plaque progression and stability. This is
urther supported by the low degree of correlation between
hese markers of oxidation (Table 4).
Oxidative modification of lipids associated with LDL and
ellular constituents contribute to endothelial dysfunction
nd inflammatory pathways associated with atherosclerosis
nd plaque development (1–3,25). A correlation between
xidative stress markers, including LOOH, and angio-
raphic measurements had been observed in an earlier study
f 1,200 patients (26). The mechanism of in vivo LDL and
rotein oxidation in human atherosclerotic lesions has been
ttributed to myeloperoxidase activity (27). Other enzy-
atic sources of reactive oxygen species include reduced
AD(P)H, lipoxygenases, xanthine oxidases, uncoupled
ndothelial nitric oxide synthases, cyclooxygenases, and
itochondria. Approaches that have been used to assess
xidative stress levels include monoclonal antibodies against
xidized LDL, quantitation of protein oxidation markers,
nd measurement of isoprostanes (28–30).
The finding in this study that LOOH, but not hs-CRP,
redicted revascularization procedures in patients with sta-
le CAD is similar to that observed with an enzymatic
ediator of oxidative stress known as lipoprotein-associated
hospholipase A2 (Lp-PLA2). The Lp-PLA2 enzyme is
ssociated with circulating LDL that hydrolyzes oxidized
hospholipids. The formation of downstream inflammatory
ediators derived from these oxidized phospholipids ac-
ounts for the pro-atherogenic effects of Lp-PLA2. Re-
ently, Lp-PLA2 was measured in 3,766 patients with stable
AD from the PEACE (Prevention of Events with
ngiotensin-Converting Enzyme Inhibition) clinical trial.
lthough both hs-CRP and Lp-PLA2 predicted acute
oronary syndromes, only Lp-PLA2 was a significant pre-
ictor of coronary revascularization after adjustment for
aseline characteristics (31). This is consistent with other
arge studies that indicate a prognostic role for oxidized
ipids and Lp-PLA2, independent of inflammatory markers
nd traditional risk factors (32).
Although amlodipine treatment produced a 31% reduc-
ion in the risk of major vascular events in these patients, a
arger decrease in serum LOOH levels was observed in
lacebo-treated subjects. To explain this apparent paradox,
eline
erum Levels
dures at Baseline
th
ures
Patients Without
Events/Procedures
p Value*SD Mean, mol/l SD
28.6 35.8 27.8 0.251
26.1 34.1 27.9 0.001
26.8 34.7 28.0 0.004
26.5 34.2 28.1 0.002
rocedures (2-sample t test).evelst Bas
OH S
Proce
nts Wi
Proced
l/le hypothesize that amlodipine may interfere with LOOH
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March 25, 2008:1196–202 Lipid Hydroperoxide Levels and Cardiovascular Riskecomposition to more atherogenic products such as dicar-
oxylic acids. The benefits of such an antioxidant mecha-
ism was described by Sakuma et al. (33) who suggested
hat an effective treatment for CAD would be one that
tabilized lipid peroxidation primary end products, thereby
nterfering with formation of secondary products such as
eactive aldehydes. These highly reactive aldehydes modify
ysine residues associated with apolipoprotein B, resulting in
xidized LDL particles that are more readily recognized by
cavenger receptors. Franzoni et al. (15) have shown that
ydroxyl radicals generated by the Fenton reaction were
apidly and efficiently scavenged by amlodipine in a manner
hat was far superior to Trolox or glutathione acid.
Serum levels of LOOH correlated directly with levels
f sICAM-1, but not IL-6 or hs-CRP. Expression of
ICAM-1 promotes the adherence and migration of new
onocytes through the endothelial barrier and is associ-
ted with increased CVD risk (34,35). Additionally,
ICAM-1 is effectively stimulated by oxidized LDL
36,37). Given the interrelationships between cytokine
xpression, angiotensin II, and reactive oxygen species,
he correlation between levels of sICAM-1 and LOOH
as not unexpected.
The implication of these data for antioxidant therapy
emains an open question because the balance of studies in
his area suggest that oxidized lipids serve as biomarkers of
AD with no clear causative role in atherogenesis. Indeed,
pidemiological studies indicate that low levels of antioxi-
ants are associated with increased risk for cardiovascular
vents; but, as recently reviewed (38,39), several large
rospective clinical trials have failed to show any benefits of
ntioxidant treatment. Possible explanations for this para-
ox may be provided by variations in trial design, baseline
ntioxidant status of participants, dosage and source of the
ntioxidants, and time of intervention relative to disease
rogression. It is also possible that vitamin E does not
eutralize relevant oxidants, such as those produced by
yeloperoxidase (2-electron oxidants) (40), and/or is less
fficient at penetrating into the atherosclerotic plaque
41,42). Alternatively, antioxidants that act at different steps
n the lipid peroxidation cascade mechanism (i.e., primary
ersus secondary end products) may have distinct effects on
REVENT: Correlation BetweenOOH and Various Biomarkers at Baseline
Table 4 PREVENT: Correlation BetweenLOOH and Various Biomarkers at Baseline
Biomarker R Value p Value
hs-CRP 0.000 0.722
sICAM-1 0.265 0.001
IL-6 0.055 0.168
TBARS 0.158 0.001
s-CRP  high sensitivity C-reactive protein; IL  interleukin; sICAM  soluble intercellular
dhesion molecule; TBARS  thiobarbituric acid reactive substances; other abbreviations as in
ables 1 and 3.he course of the disease.
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